It was further demonstrated that combination with HER inhibitor lapatinib prevented MAPK rebound and sensitized BRAF-mutant thyroid cancer cells to BRAF or MEK inhibitors [15]. The gene discussed is MAP2K7; the disease is thyroid gland carcinoma.